Exact sciences

Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan

Retrieved on: 
Monday, August 16, 2021
Biology, Breast cancer, Colon, Epic Sciences, Electric Bond and Share Company v. Securities and Exchange Commission, Recurrence, Program, Lymph, Exact Sciences (company), MCRPC, CEO, News, Risk, Genomic Health, Ministry, Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer classification, Research, Annual report, Security (finance), Patient, Genomics, List of health departments and ministries, Growth, Software, Breast, Neoplasm, Exact sciences, Cancer, DCIS, Nasdaq, Woman, MHLW, Prostate cancer, Dietary supplement, Medical imaging

Breast cancer is the most common cancer in Japanese women, and more than 90,000 new breast cancer cases were diagnosed in Japan in 2020.i The Oncotype DX Breast Recurrence Score Program approved in Japan combines the Oncotype DX Breast Recurrence Score test and software developed for the Japanese market.

Key Points: 
  • Breast cancer is the most common cancer in Japanese women, and more than 90,000 new breast cancer cases were diagnosed in Japan in 2020.i The Oncotype DX Breast Recurrence Score Program approved in Japan combines the Oncotype DX Breast Recurrence Score test and software developed for the Japanese market.
  • "MHLW's approval of Oncotype DX is great news for breast cancer patients in Japan and reflects the powerful evidence backing the Oncotype DX test," said Kevin Conroy, chairman and CEO.
  • In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.

Breast Cancer Diagnostics Global Market Report 2020-2030: COVID-19 Impacts on Procedures, Growth and Changes - ResearchAndMarkets.com

Retrieved on: 
Friday, August 13, 2021
Health, Oncology, Comparative genomic hybridization, Abbott Laboratories, Breast cancer, FISH, Southwest Medical Center, CAGR, EGFR, Genomic Health, Disease, BRCA, IHC, COVID-19, In situ hybridization, Acquisition, Gene expression, Organization, Patient, Growth, Association for Molecular Pathology v. Myriad Genetics, Inc., Breast, Technology, Incidence, Exact sciences, Death, Hospital, Fujifilm, Hologic, Cancer, Diagnosis, Siemens, Woman, GE Healthcare, CGH, Mammography, Biopsy, Pharmaceutical industry, Medical imaging

The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce breast cancer diagnostics devices.

Key Points: 
  • The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce breast cancer diagnostics devices.
  • The high cost of diagnosis of breast cancer is a key factor that hinders the growth of the market for diagnostics of breast cancer.
  • Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market.
  • By Cancer Type: BRCA Breast Cancer; ER & PR Breast Cancer; HER 2 Breast Cancer; EGFR Mutation Test Breast Cancer; Others

More Stars Join Stand Up To Cancer Roadblock Fundraising Telecast And Streaming Event

Retrieved on: 
Thursday, August 12, 2021
MLB, Multimedia, Mj Rodriguez, Van Andel Institute, Awareness, SU2C, Tobacco Products Scientific Advisory Committee, PT, CEO, Luminary, Bristol Myers Squibb, Canadian Cancer Society, Noreen Fraser Foundation, UP2U, Entertainment Industry Foundation, Disease, Multiple myeloma, American Association, SungWon Cho, Death, Jackbox Games, Lustgarten Foundation for Pancreatic Cancer Research, FAC, Investor, Research, Pancreatic cancer, FDA, Patient, Mastercard, Social media, Exact sciences, Academy Awards, Stand Up to Cancer, Cancer, Stand Up, Association, Diagnosis, Kate, Hoffmann-La Roche, Major League Baseball, IJustine, AACR, Industry, T-cell acute lymphoblastic leukemia, Common, American Association for Cancer Research, UnitedHealth Group, Film, Broadcasting, Pharmaceutical industry

LOS ANGELES, Aug. 12, 2021 /PRNewswire/ --Stand Up To Cancer (SU2C) has added more star power to the lineup of its seventh biennial roadblock televised fundraising special .

Key Points: 
  • LOS ANGELES, Aug. 12, 2021 /PRNewswire/ --Stand Up To Cancer (SU2C) has added more star power to the lineup of its seventh biennial roadblock televised fundraising special .
  • The week-long fundraising initiative, ending on Saturday, August 21, will feature exciting live streams, inspirational patient stories, and a dance challenge by pediatric cancer patient and dancer Orli Halpern.
  • During the show, viewers will be immersed in first-hand stories featuring families who have been impacted by cancer.
  • The initiative aims to increase diverse enrollment in cancer clinical trials, fund innovative research that addresses cancer inequities, and raise awareness of the importance of cancer screenings.